These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 19236457)
1. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Harbo T; Andersen H; Hess A; Hansen K; Sindrup SH; Jakobsen J Eur J Neurol; 2009 May; 16(5):631-8. PubMed ID: 19236457 [TBL] [Abstract][Full Text] [Related]
2. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. Misbah SA; Baumann A; Fazio R; Dacci P; Schmidt DS; Burton J; Sturzenegger M J Peripher Nerv Syst; 2011 Jun; 16(2):92-7. PubMed ID: 21692906 [TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Harbo T; Andersen H; Jakobsen J Neurology; 2010 Oct; 75(15):1377-80. PubMed ID: 20938030 [TBL] [Abstract][Full Text] [Related]
4. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531 [TBL] [Abstract][Full Text] [Related]
5. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Markvardsen LH; Christiansen I; Jakobsen J Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495 [TBL] [Abstract][Full Text] [Related]
15. Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin. Markvardsen LH; Christiansen I; Andersen H; Jakobsen J Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):409-12. PubMed ID: 26096187 [TBL] [Abstract][Full Text] [Related]
16. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG. Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions. Bayas A; Gold R; Naumann M J Neurol Sci; 2013 Jan; 324(1-2):53-6. PubMed ID: 23095259 [TBL] [Abstract][Full Text] [Related]
18. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148 [TBL] [Abstract][Full Text] [Related]
19. High-Dose Subcutaneous Immunoglobulin in Patients With Multifocal Motor Neuropathy: A Nursing Perspective. Rasutis VM; Katzberg HD; Bril V J Infus Nurs; 2017; 40(5):305-312. PubMed ID: 28885479 [TBL] [Abstract][Full Text] [Related]
20. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. Berger M; Murphy E; Riley P; Bergman GE; South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]